
Novo Nordisk licenses a once-weekly oral GLP-1/GIP candidate, uniQure reports 48-month Huntington’s disease data, and AstraZeneca invests $2 billion in Summit Therapeutics.
by James D. Williams, Virginia Polytechnic Institute and State University, Jeffrey B. Birch, and Steven Walfish Statistics don't lie, but if you don't include appropriate data, the resulting statistical analyses can be misleading. In biopharmaceutical development, if the variability from several different microplates is not addressed, assays testing the relative potency against a standard can be inaccurate. A statistical method that accounts for plate-to-plate heterogeneity is needed ? and presented here.
over 23 years ago
Sumeria to Satellites: Evolution of the Bioreactorover 23 years ago
Patent Law: Extracting Maximum Value from Your Patent Portfolioover 23 years ago
Inside Washington: Medication Safety in the Limelightover 23 years ago
Part 11 Is Not Going Away: The New Electronic Records Draft Guidanceover 23 years ago
Survival Strategies: The Life Sciences Industry Turns to eLearning





